Guillain-Barré syndrome after combined CHOP and rituximab therapy in non-Hodgkin lymphoma.
Terenghi
Fabrizia
F
Ardolino
Gianluca
G
Nobile-Orazio
Eduardo
E
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D020275:Guillain-Barre Syndrome / Q000139:chemically induced* / Q000503:physiopathology* / Q000628:therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D010951:Plasma Exchange; D011241:Prednisone / Q000009:adverse effects; D000069283:Rituximab; D014750:Vincristine / Q000009:adverse effects
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D016756:Immunoglobulins, Intravenous; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone; D008775:Methylprednisolone